This Article Full Text Full Text (PDF) Publisher's Note Erratum (v26,p4697) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hochster, H. S. Articles by Hedrick, E. Search for Related Content PubMed Articles by Hochster, H. S. Articles by Hedrick, E. Social Bookmarking                            What's this?

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen L. Cohn, Lucas Wong, Louis Fehrenbacher, Yousif Abubakr, M. Wasif Saif, Lee Schwartzberg, Eric Hedrick

From the New York University Cancer Institute, New York, NY; Florida Cancer Specialists, Fort Myers, FL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; sanofi-aventis, Bridgewater, NJ; Sarah Cannon Cancer Center, Nashville; West Cancer Clinic, Memphis, TN; Rocky Mountain Cancer Center, Denver, CO; Scott & White Hospital, Center for Cancer Prevention and Care, Temple, TX; Department of Oncology/Hematology, Kaiser Permanente, Vallejo Medical Center, Vallejo, CA; Florida Oncology Association, Jacksonville, FL; Yale University School of Medicine, New Haven, CT; and Genentech BioOncology, South San Francisco, CA

Corresponding author: Howard S. Hochster, MD, New York University Cancer Institute, 160 East 34th St, New York, NY 10016; e-mail: Howard.Hochster{at}med.nyu.edu

Purpose To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC).

Patients and Methods Patients with histologically documented metastatic or recurrent CRC and no prior treatment for advanced disease were randomly assigned to mFOLFOX6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin), bFOL (bolus FU and low-dose LV with oxaliplatin), or CapeOx (capecitabine with oxaliplatin), respectively (Three Regimens of Eloxatin Evaluation [TREE-1]). The study was later modified such that subsequent patients were randomized to the same regimens plus bevacizumab (TREE-2).

Results A total of 150 and 223 patients were randomly assigned in the TREE-1 and TREE-2 cohorts, respectively. Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point). CapeOx toxicity in TREE-1 included grade 3/4 diarrhea (31%) and dehydration (27%); capecitabine dose reduction to 1,700 mg/m²/d in TREE-2 resulted in improved tolerance. Overall response rates were 41%, 20%, and 27% (TREE-1) and 52%, 39%, and 46% (TREE-2); median overall survival (OS) was 19.2, 17.9, and 17.2 months (TREE-1) and 26.1, 20.4, and 24.6 months (TREE-2). For all treated patients, median OS was 18.2 months (95% CI, 14.5 to 21.6; TREE-1) and 23.7 months (95% CI, 21.3 to 26.8; TREE-2).

Conclusion The addition of bevacizumab to oxaliplatin and fluoropyrimidine regimens is well tolerated as first-line treatment of mCRC and does not markedly change overall toxicity. CapeOx tolerability and efficacy is improved with reduced-dose capecitabine. First-line oxaliplatin and fluoropyrimidine-based therapy plus bevacizumab resulted in a median OS of approximately 2 years.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. DiBartolomeo, M.-A. Mazier, J.-L. Canon, V. Georgoulias, M. Peeters, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann. Onc., November 1, 2009; 20(11): 1842 - 1847. [Abstract] [Full Text] [PDF]

				F. Montagnani, C. Migali, and G. Fiorentini Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point? J. Clin. Oncol., October 1, 2009; 27(28): e132 - e133. [Full Text] [PDF]

				A. Grothey and D. J. Sargent Reply to F. Montagnani et al J. Clin. Oncol., October 1, 2009; 27(28): e134 - e135. [Full Text] [PDF]

				A. Grothey Review: Medical treatment of advanced colorectal cancer in 2009 Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68. [Abstract] [PDF]

				M. J. Overman, G. R. Varadhachary, S. Kopetz, R. Adinin, E. Lin, J. S. Morris, C. Eng, J. L. Abbruzzese, and R. A. Wolff Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater J. Clin. Oncol., June 1, 2009; 27(16): 2598 - 2603. [Abstract] [Full Text] [PDF]

				C. Carlomagno, A. Farella, L. Bucci, F. P. D'Armiento, G. Pesce, S. Pepe, L. Cannella, R. Pacelli, A. De Stefano, R. Solla, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study Ann. Onc., May 1, 2009; 20(5): 906 - 912. [Abstract] [Full Text] [PDF]

				S. M Gressett and S. R Shah Intricacies of Bevacizumab-Induced Toxicities and Their Management Ann. Pharmacother., March 1, 2009; 43(3): 490 - 501. [Abstract] [Full Text] [PDF]